X4 Pharmaceuticals Announces $125M Capital Infusion From $105M Sale of Priority Review Voucher And $20M Drawdown From Existing Loan Facility, Extends Projected Cash Runway Into Late 2025
X4 Pharmaceuticals Announces $125M Capital Infusion From $105M Sale of Priority Review Voucher And $20M Drawdown From Existing Loan Facility, Extends Projected Cash Runway Into Late 2025
X4 Pharmaceuticals 宣佈從 1.05 億美元的優先審核券銷售中獲得 1.25 億美元的資本注入，並從現有貸款機制中提取 2,000 萬美元，將預計現金流延長至 2025 年末
X4 Pharmaceuticals 宣佈從 1.05 億美元的優先審核券銷售中獲得 1.25 億美元的資本注入，並從現有貸款機制中提取 2,000 萬美元，將預計現金流延長至 2025 年末
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。